Antiparasitics in Animal Health: Quo Vadis?

Antiparasitics acting on endo- or ectoparasites represent the second largest segment of the global animal health market, accounting for 23% of market share. However, relatively few novel antiparasitic agents have been introduced into the market during recent decades. One exception, and a groundbreaking 21st century success story, are the isoxazolines, whose full potential has not yet been entirely explored. Unfortunately, resistance issues are present across most parasitic diseases, which generates a clear market need for novel resistance-breaking antiparasitics with new modes/mechanisms of action. Recent advances in science and technologies strongly suggest that the time is right to invest in new modalities such as parasitic vaccines or in environmentally friendly interventions.

Automated summary

Antiparasitics acting on endo- or ectoparasites represent the second largest segment of the global animal health market, but few novel antiparasitic agents have been introduced in recent years. To address resistance issues, there is a clear need for novel antiparasitics with new modes/mechanisms of action.